Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis
- PMID: 33748846
- DOI: 10.1093/eurheartj/ehab158
Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis
Comment in
-
The neutrophil-lymphocyte ratio: considerations for clinical application.Eur Heart J. 2021 Jun 7;42(22):2216-2217. doi: 10.1093/eurheartj/ehab166. Eur Heart J. 2021. PMID: 33748837 No abstract available.
Comment on
-
The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials.Eur Heart J. 2021 Mar 1;42(9):896-903. doi: 10.1093/eurheartj/ehaa1034. Eur Heart J. 2021. PMID: 33417682 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
